Abstract: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
Type:
Application
Filed:
November 27, 2013
Publication date:
October 30, 2014
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Jefferson J. Gregory, Michael T. Nordsiek
Abstract: Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.
Type:
Application
Filed:
March 14, 2014
Publication date:
September 18, 2014
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Douglas Anthony Bakan, Steven B. Newhard, Nilendu Sen, Amol Subhash Mandhare, Tushar Deoram Jadhav, Mukesh Kumar
Abstract: The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.
Type:
Grant
Filed:
October 18, 2011
Date of Patent:
September 16, 2014
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Mary L. Owens, Terrance L. Fox, Angela M. Ginkel
Abstract: The present disclosure provides aqueous-based gel formulations of metronidazole useful for a variety of purposes, including topical application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with rosacea.
Type:
Application
Filed:
December 20, 2013
Publication date:
July 24, 2014
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Michael T. Nordsiek, Kodumudi S. Balaji
Abstract: Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.
Type:
Grant
Filed:
May 31, 2013
Date of Patent:
July 15, 2014
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Mitchell S. Wortzman, Rhoda Narins, Xiaoming Lin
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Type:
Application
Filed:
November 27, 2013
Publication date:
July 3, 2014
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Michael T. Nordsiek, Jefferson J. Gregory
Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
Type:
Grant
Filed:
August 23, 2010
Date of Patent:
May 13, 2014
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Mitchell Wortzman, R. Todd Plott, Steven B. Newhard, David Watt
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Type:
Grant
Filed:
July 26, 2012
Date of Patent:
February 4, 2014
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Michael T. Nordsiek, Jefferson J. Gregory
Abstract: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
Type:
Grant
Filed:
July 18, 2012
Date of Patent:
December 3, 2013
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Jefferson J. Gregory, Michael T. Nordsiek
Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”).
Type:
Application
Filed:
May 15, 2013
Publication date:
September 26, 2013
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Jefferson J. Gregory, Michael T. Nordsiek
Abstract: The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
Type:
Application
Filed:
August 6, 2012
Publication date:
August 15, 2013
Applicant:
MEDICIS PHARMACEUTICAL CORPORATION
Inventors:
Michael T. NORDSIEK, Sharon F. LEVY, James H. LEE, James H. KULP, Kodumudi S. BALAJI, Tze-Chiang MENG, Jason J. WU, Valyn S. BAHM, Robert BABILON
Abstract: This disclosure is directed to the use of complementary or combination photodynamic therapy and topical therapy with a lower dosage strength imiquimod formulation for treating actinic keratosis.
Type:
Application
Filed:
September 14, 2012
Publication date:
July 25, 2013
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Michael H. Gold, Joel L. Cohen, Girish S. Munavalli, Tze-Chiang Meng
Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.
Type:
Application
Filed:
March 4, 2013
Publication date:
July 11, 2013
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.
Type:
Application
Filed:
September 10, 2012
Publication date:
June 13, 2013
Applicant:
Medicis Pharmaceutical Corporation
Inventors:
Richard L. Miller, James H. Lee, Mary L. Owens
Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
June 4, 2013
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
Abstract: Methods for applying injectable fillers are provided. In some embodiments, the methods can extend effectiveness of the injectable filler. In some embodiments, the methods can provide for an elevated level of effectiveness of the injectable filler. In some embodiments, the methods can prolong the effectiveness of the injectable filler.
Type:
Grant
Filed:
August 1, 2008
Date of Patent:
June 4, 2013
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Mitchell S. Wortzman, Rhoda Narins, Xiaoming Lin
Abstract: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.
Type:
Grant
Filed:
March 12, 2004
Date of Patent:
April 23, 2013
Assignee:
Medicis Pharmaceutical Corporation
Inventors:
Richard L. Miller, James H. Lee, Mary L. Owens